Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer

Head and Neck

Volumn 24, Issue 8, 2002, Pages 792-799

  Lin, Derrick T ^a   Subbaramaiah, Kotha ^b   Shah, Jatin P ^a   Dannenberg, Andrew J ^b   Boyle, Jay O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemoprevention; Cyclooxygenase; Head and neck; Prostaglandins; Squamous cell carcinoma

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE; XENOBIOTIC AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; HEAD AND NECK CANCER; HUMAN; IMMUNOSURVEILLANCE; LEUKOPLAKIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; XENOBIOTIC METABOLISM; BIOSYNTHESIS; CANCER INVASION; HEAD AND NECK TUMOR; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE INHIBITORS; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNE TOLERANCE; INFLAMMATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; SULFONAMIDES; SUPPORT, U.S. GOV'T, P.H.S.; UP-REGULATION; XENOBIOTICS; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036023220     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10108     Document Type: Review

References (97)

1. Cancer Statistics
2. Second primary tumors in patients with oral cancer
3. Cyclo-oxygenase-2: A pharmacological target for the prevention of cancer
4. 1; molecular mechanisms and therapeutic utility
5. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
6. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor- and phorbol ester
7. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
8. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells
9. Benzo[a]pyrene upregulates cyclooxygenase-2 gene expression in oral epithelial cells
10. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor
11. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells
12. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous cell carcinoma cells
13. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2
14. Inhibition of cyclooxygenase-2 gene expression by p53
15. The incidence of p53 mutations increases with progression of head and neck cancer
16. Prostaglandin-like material extracted from squamous cell carcinomas of the head and neck
17. Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study
18. Prostaglandins and human lung carcinomas
19. Altered eicosanoid levels in human colon cancer
20. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
21. Host cyclooxygenase-2 modulates carcinoma growth
22. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients
23. Regulation of immune response by prostaglandins
24. Suppression of human T-cell mitogenesis by prostaglandin; existence of a prostaglandin producing suppressor cell
25. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
26. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
27. Aspirin use and reduced risk of fatal colon cancer
28. Aspirin and the risk of colorectal cancer in women
29. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
30. Nonsteroidal antiinflammatory drugs and breast cancer
31. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent
32. Modulation of rat mammary carcinogenesis by indomethacin
33. Aspirin and reduced risk of esophageal carcinoma
34. Inhibition of lung tumorigenesis by sulindac: Comparison of two experimental protocols
35. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug during different stages of rat colon tumor development
36. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
37. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
38. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
39. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin
40. Oral mucosal tumor inhibition by ibuprofen
41. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
42. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
43. Cyclooxygenase-2 expression in human esophageal carcinoma
44. Cyclooxygenase-2 expression in hepatocellular carcinoma
45. Expression of cyclooxygenase-2 in human gastric carcinoma
46. Cyclooxygenase-2 expression is upregulated in common colonic, pulmonary and mammary tumors
47. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
48. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
49. Expression of cyclooxygenase-2 in human lung carcinoma
50. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
51. Expression of cyclooxygenase-2 (COX-2) is human invasive transitional cell carcinoma (TCC) of the urinary bladder
52. Cyclooxygenase-2 is overexpressed in human cervical cancer
53. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
54. Δ716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2)
55. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
56. Chemopreventive activity of celecoxib, a specific cyclo-oxygenase-2 inhibitor, against colon carcinogenesis
57. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
58. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
59. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet -induced skin carcinogenesis
60. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398
61. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
62. Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide
63. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
64. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells
65. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
66. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model
67. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
68. Prostaglandin synthetase dependent activation of 7,8-dihydro-7, 8-dihydroxy-geno (a) pyrene to mutagenic derivatives
69. Prostaglandin H synthase and xenobiotic oxidation
70. Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma
71. Carcinogen substrate specificity of human COX-1 and COX-2
72. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
73. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines
74. Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis
75. Subversion of immune system by tumor cells and role of prostaglandins
76. Inhibition of murine natural killer cell activity by prostaglandins
77. Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E
78. Prostaglandin inhibition of T-cell proliferation is mediated at two levels
79. Regulation of macrophage tumor necrosis factor production by prostaglandin E2
80. 2 inhibits TNF-alpha release via a mechanism involving IL-10
81. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis
82. Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis
83. Indomethacin enhancement of immunocompetence in melanoma patients
84. Indomethacin-mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients
85. What is the evidence that tumors are angiogenesis dependent?
86. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
87. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
88. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44
89. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522
90. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
91. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study
92. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
93. Combinatorial chemoprevention of intestinal neoplasia
94. 13-cis-retinoic acid in the treatment of oral leukoplakia
95. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
96. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme
97. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU